Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 3,714 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Muscle Disorders Clear all

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: N803 plus Bacillus Calmette-Guerin (BCG); Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Chronic Pain, Musculoskeletal Pain
Interventions: GetActive+; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke
Interventions: Task-specific PCMS, Task-specific sham-PCMS, PCMS-rest; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Acute Myeloid Leukemia, Aml, ALL, Medulloblastoma, Acute Lymphoblastic Leukemia ,Lymphomas
Interventions: my.naviGATE Digital Tool; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 15 Years to 24 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy
Interventions: PF-06939926; Genetic
Lead sponsor: Pfizer; Industry
Eligibility: 4 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 22
States / cities: Los Angeles, California • Durham, North Carolina • Salt Lake City, Utah

Conditions: Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions: Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC); Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obesity & Overweight, Diabetes (DM)
Interventions: Glucagon-Like Peptide-1 Agonist (GLP-1); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: RGX-202; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 1 Year and older · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 19
States / cities: Little Rock, Arkansas • Orange, California • Palo Alto, California + 16 more

Conditions: Hand Injuries, Trigger Finger
Interventions: Oval-8 ® Orthosis, Cortisone injection only; Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab, Placebo, Corticosteroids; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 21 more

Conditions: COVID-19
Interventions: Q-NRG Metobolic Cart Device, MuscleSound Ultrasound, Multifrequency Bioimpedance Spectroscopy; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Limb Girdle Muscular Dystrophy
Interventions: SRP-9003; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Columbus, Ohio • Memphis, Tennessee

Conditions: Lateral Epicondylitis, Unspecified Elbow
Interventions: Embozene particles; Device
Lead sponsor: Siddharth Padia, MD; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Amyotrophic Lateral Sclerosis, Muscle Cramp
Interventions: TJ-68, Placebo; Drug
Lead sponsor: Hiroshi Mitsumoto; Other
Eligibility: 20 Years to 84 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • New York, New York

Conditions: Chronic Exertional Compartment Syndrome
Interventions: Definity; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-210, Gemcitabine, MMC; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 38
States / cities: Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more

Conditions: Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions: KYV-101; Drug
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2041
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atrophy, Disuse, Muscle Atrophy, Muscular Disorders, Atrophic, Disuse Atrophy, Disuse Atrophy Muscle of Thigh
Interventions: Unilateral leg immobilization, Contralateral active leg; Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years to 39 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
Interventions: tizanidine hydrochloride capsule; Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 16
States / cities: Tucson, Arizona • Encinitas, California • Northridge, California + 12 more

Conditions: Primary Mitochondrial Disease
Interventions: KL1333, Placebo; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Orange, California • San Diego, California • San Francisco, California + 15 more

Conditions: Disuse Osteoporosis, Atrophy, Disuse, Nervous System, Structural; Marker, Skeletal Muscle Hypertrophy
Interventions: Electrical Stimulation, Stand Retraining with Body Weight Support (BWS); Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 58 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Pompe Disease
Interventions: respiratory muscle strength training; Other
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neuromuscular Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Improving Health for Older Adults With Pain Through Engagement (Open-pilot)

PCMS Task After Moderate-to-severe Stroke

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

Microvascular and Fibrosis Imaging Study

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Conservative Treatment of Trigger Finger

Familial Investigations of Childhood Cancer Predisposition

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Elbow Artery Embolization for Tennis Elbow

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

Diagnosing Compartment Syndrome With SHAPE vs Elastography

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Molecular Mechanisms Underlying Anabolic Resistance to Protein Intake During Muscle Disuse

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes

The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease

Phenotype/Genotype Correlations in Neuromuscular Disorders